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ABSTRACT
The aim of the present study was to evaluate antimicrobial susceptibility patterns with special reference 
to multidrug resistance, susceptibility to ciprofloxacin, and bacteriophage typing of Salmonella enterica 
serotype Typhi isolated from blood sent for culture in a tertiary-care teaching hospital in eastern Nepal 
during January 2000–December 2004. In total, 132 strains of S. enterica Typhi, isolated from 2,568 
blood culture samples collected from cases of suspected enteric fever, were tested for susceptibility to 
commonly-used antimicrobials by the disc-diffusion method. There were 35 multidrug-resistant strains. 
None of the isolates were resistant to ciprofloxacin. Of 52 isolates tested for minimum inhibitory concen-
tration (MIC) of ciprofloxacin, 36 (69.23%) showed reduced susceptibility (MIC ≥0.25 mg/L). Of 112 
strains tested for nalidixic acid susceptibility, 86 (76%) were resistant. Strains with reduced susceptibility 
to ciprofloxacin and resistance to nalidixic acid could be correlated. The commonest phage type was E1. 
Nalidixic acid susceptibility could be a useful screening test for the detection of decreased susceptibility 
of S. Typhi to ciprofloxacin, a drug which is commonly used even for minor ailments in this area. 
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INTRODUCTION
Typhoid fever, a severe systemic illness, caused by Sal-
monella enterica serotype Typhi, is still an important 
public-health problem in many developing countries, 
including Nepal. According to a recently-revised global 
estimate, it causes 21.6 million illnesses every year, re-
sulting in 216,500 deaths (1).
  Multidrug-resistant S. Typhi (MDRST) is epi-
demiologically defined as strains resistant to any two 
antimicrobials in vitro even if the antimicrobials tested 
are known to be clinically ineffective (2). A more use-
ful definition of MDRST is reserved for strains resistant 
to all three first-line antityphoidal antimicrobial agents, 
namely ampicillin, chloramphenicol, and trimethoprim-
sulphamethoxazole (2).
  Typhoid fever, caused by MDRST, has become 
a significant cause of morbidity and mortality over 
recent years. These strains have also caused outbreaks 
throughout the world, especially in South America, In-
dian subcontinent, Africa, and South-East Asia (3,4). 
The incidence of MDRST is reported to be as high as 
60%, although there are some reports noting its decline 
(5-8). 
  With the emergence of MDRST, fluoroquinolo-
nes have gained importance for the treatment of en-
teric fever in recent years. There are reports of pro-
longed defervescence after ciprofloxacin therapy (9-12). 
Strains, isolated from these cases, exhibit susceptibility 
to ciprofloxacin in disc-diffusion testing, but minimum 
inhibitory concentrations (MICs) for these strains are 
about 10 times higher than fully-susceptible strains. 
This reduced susceptibility is probably the cause for 
poor clinical response to treatment. Isolates of S. Typhi 
with decreasd susceptibility to ciprofloxacin have been 
found to be nalidixic acid-resistant. These nalidixic 
acid-resistant S. Typhi (NARST) require higher concen-
trations of ciprofloxacin for inhibition (4,9,10).
  A considerable variation has been noted in the 
antimicrobial susceptibility patterns among isolates of 
S. Typhi as suggested in various studies conducted in different geographical locations (7,11-17). Knowledge 
of the prevalence of S. Typhi and their antimicrobial 
susceptibility patterns is of utmost importance in the 
institution of appropriate antimicrobial therapy. Resist-
ant Salmonellae and failure of ciprofloxacin therapy 
have been matters of concern in the reports of some 
studies conducted in central Nepal (8,18-20). Phage 
type is an important epidemiological marker to study 
the movement of organisms and their spread from one 
geographic locale to another. Data on the susceptibility 
patterns and phage type prevalence of S. Typhi isolates 
in eastern Nepal are lacking. The present study was, 
therefore, undertaken to determine the antimicrobial 
susceptibility patterns of local isolates of S. Typhi with 
special reference to their multidrug resistance and re-
duced susceptibility to ciprofloxacin and bacteriophage 
types. 
MATERIALS AND METHODS
Blood samples for culture were obtained from pa-
tients who presented to the B.P. Koirala Institute of 
Health Sciences (BPKIHS) hospital, a tertiary-care 
teaching hospital in eastern Nepal, with a history of 
fever of variable duration from January 2000 to Decem-
ber 2004. Brain-heart infusion (BHI) broth, which es-
tablishes the growth of all common pathogens causing 
bacteraemia/septicaemia was used as a culture medium. 
Collection of blood, incubation, and subculture(s) onto 
blood agar and MacConkey agar were done as per the 
standard methods (21). Suspected non-lactose-ferment-
ing colonies were further processed and identified by bio-
chemical reactions and confirmed by group and type-
specific Salmonella antisera (Murex Biotech, England)
  Antimicrobial susceptibility was determined by the 
Kirby-Bauer disc-diffusion method performed on Mull-
er-Hinton agar plates against ampicillin (10 µg), ceftri-
axone (30 µg), chloramphenicol (30 µg), ciprofloxacin 
(5 µg), co-trimoxazole (25 µg), gentamicin (10 µg), 
and nalidixic acid (30 µg) (Hi Media Laboratory Ltd., 
Mumbai, India) (22).
  The nalidixic acid-susceptibility test for Salmonella 
was introduced in our centre in 2001; thus, only S. Typhi 
isolated from 2001 onwards were tested for it.
  The disk strength and zone-size interpretation was 
in accordance with the National Committee for Clinical 
Laboratory Standards (NCCLS) (22).
  MIC of ciprofloxacin to 24 of 26 nalidixic acid-sus-
ceptible S. Typhi (NASST) and 28 randomly-selected 
NARST was determined by the agar-dilution method as 
per the NCCLS standards (23). 
  Fifty-four strains of S. Typhi, isolated till mid-2002, 
were sent to the National Phage Typing Centre, Lady 
Hardinge Medical College, New Delhi, for phage typing 
and biotyping. Strains isolated after that period could 
not be sent.
RESULTS
In total, 132 strains of S. Typhi were isolated from 2,568 
blood culture samples submitted to the Microbiology 
Unit of Clinical Laboratory Services, BPKIHS, from 
patients of suspected enteric fever. The isolates were 
from all age-groups, the median age being 19 years. The 
male-to-female ratio was 2.1:1.
  Table 1 shows the antimicrobial susceptibility pat-
terns of S. Typhi. Of the 132 isolates, 35 (26.4%) 
were MDR showing simultaneous resistance to ampi-
cillin, chloramphenicol, and co-trimoxazole which are 
first-line anti-typhoidal drugs. The decreasing trend of 
MDRST was observed in 2004 (p=0.04, Cochran Ar-
Table 1. Resistance patterns (%) of S. Typhi isolates (n=132)
Antimicrobial  2000
(n=20)
2001
(n=30)
2002
(n=25)
2003
(n=34)
2004
(n=23)
Total
(n=132)
Ampicillin 7 (35) 13 (43.3) 8 (32) 11 (32) 1 (4.34) 40 (30)
Co-trimoxazole 7 (35) 10 (33.5) 6 (24) 12 (35.29) 1 (4.34) 36 (27)
Chloramphenicol 7 (35) 11 (36.6) 6 (24) 11 (32.35) 1 (4.34) 36 (27)
Ciprofloxacin 0   0 0   0 0   0
Ceftriaxone 0   0 0   0 0   0
Nalidixic acid NT 23 (76.6) 19 (76) 28 (82.3) 16 (69.5) 86 (77)
Gentamicin 0   1 (3.33) 0   1 (2.94) 0   2 (1.5)
Multi-drug resistance    
  (ampicillin+co-trimoxazole  
  +chloramphenicol)   7 (35) 10 (33.3) 6 (24) 11 (32) 1 (4.35) 35 (26)
Figures in parentheses indicate percentages; NT=Not tested
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floxacin and ceftriaxone. Nalidixic acid susceptibility 
testing was done for 112 isolates, of which 86 (76%) 
were resistant.
  MIC of ciprofloxacin was determined for 52 isolates, 
24 NASST, and 28 NARST. Sixteen (30.67%) had MIC 
<0.25 mg/L, and 36 (69.23%) had ≥0.25 mg/L. Seven 
isolates with 0.25 mg/L, 14 with 0.5 mg/L, and seven 
with one mg/L were resistant to nalidixic acid. Eight iso-
lates with decreased ciprofloxacin susceptibility were 
sensitive to nalidixic acid (Table 2).
  Phage typing was done for 54 isolates of S. Typhi. 
The majority (n=35, 64.8%) of the isolates were of 
phage type E1, and the remaining isolates belonged to 
different phage groups: A (6), UVS1 (2), UVS2 (2), 
and D1 (1). Six were Vi-negative, and one had degraded 
Vi. Of the 35 E1 strains, 20 were MDR. Of the 35 MDR 
strains, 22 were phage-typed, of which 20 belonged to 
the E1 type. Forty-nine (90.5%) strains were biotype 1, 
and five strains (9.5%) were biotype II. 
DISCUSSION
Enteric fever is a major public-health problem in 
developing countries, including Nepal.
  Prompt institution of appropriate antimicrobial 
therapy can reduce morbidity and mortality associated 
with this illness. Since 1948, chloramphenicol had been 
the mainstay of treatment of enteric fever until 1972 
when chloramphenicol-resistant typhoid fever became a 
major problem. Outbreaks of typhoid fever occurred 
frequently in Mexico, India, Viet Nam, Thailand, Korea, 
and Peru. Although initially susceptible to ampicillin 
and co-trimoxazole, S. Typhi strains resistant simultane-
ously to all the first-line anti-typhoidal drugs emerged 
in the 1970s. Since then, these MDR strains have spread 
to Mexico, India, and other regions in an epidemic 
form and have rapidly emerged worldwide (4, 6). In the 
present study, the number of MDRST among the total 
isolates of S. Typhi was 35 (26.5%) which is high and is 
comparable with other reports from the Indian sub-
continent (3-5). Some studies have, however, reported 
its decline (6-8). In the present study too, a similar 
pattern was observed. The number of MDR strains 
had declined towards the end of 2003 and continued 
through 2004, and this decreasing trend was statisti-
cally significant (p=0.04).
  The phage type E1 appeared to be the dominant 
type in our series. It was also observed that 20 of the 
22 MDR strains belonged to the phage type E1. These 
findings are concordant with reports from neighbour-
ing India, suggesting cross-over of strains due to human 
traffic between the two countries (6,11,13-15). 
  With the emergence of MDR S. Typhi, quinolone, 
particularly fluoroquinolones, has been widely used and 
recommended as an alternative drug for typhoid fever 
where the first-line drug is no longer in use. Fluoroquinolo-
nes, available since the 1980s, have good in-vitro suscep-
tibility and in-vivo efficacy against Salmonellae, includ-
ing S. Typhi. Nalidixic acid, the prototype and the first 
member of the quinolone group, is now seldom used due 
to the emergence of resistant serotypes of Salmonella. 
It has also been observed that nalidixic acid-resistant S. 
Typhi has decreased susceptibility to fluoroquinolones. 
The clinical response to these agents in patients infected 
with NARST is greatly inferior to the response in those 
infected with nalidixic acid-susceptible strains. The 
prolonged defervescence or treatment failure in typhoid 
fever associated with ciprofloxacin and other fluoroqui-
nolone therapy have been reported from many centres 
(9,10-12,24,25). Since 1993, S. Typhi with decreased 
susceptibility to ciprofloxacin has been isolated with an 
increasing frequency in Viet Nam (4,11). Subsequently, 
an extensive outbreak of NARST with decreased sus-
ceptibility to ciprofloxacin occurred in Tajikistan (26). 
Threlfall et al. observed that isolation of S. typhi with 
reduced susceptibility to ciprofloxacin increased from 
0.9% in 1991 to 23% in 1999 in the Central Public 
Health Laboratory, UK. Most of those isolates were 
from patients returned recently from the Indian subcon-
Table 2. Results of nalidixic acid-screening test and MIC of ciprofloxacin
NA susceptibility 
disc-diffusion test 
(n=52)
MIC of ciprofloxacin
0.015 mg/L 0.03 mg/L 0.06 mg/L 0.12 mg/L 0.25 mg/L 0.5 mg/L 1 mg/L
NASST (24) 5 8 1 2  5   3 0
NARST (28) 0 0 0 0  7 14 7
Total 5 8 1 2 12 17 7
MIC=Minimum inhibitory concentration; NA=Nalidixic acid; NASST=Nalidixic acid-susceptible Salmonella 
Typhi; NARST=Nalidixic acid-resistant Salmonella Typhi
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is similar to the reports from various series, suggesting 
that these strains are endemic in several countries of the 
Indian subcontinent (4,6,10,25,27).
  The current MIC breakpoints for Enterobacteriaceae, 
including S. enterica for ciprofloxacin, are <1 mg/L 
and ≥4 mg/L for susceptibility and resistance respective-
ly. S. Typhi with reduced susceptibility to ciprofloxacin 
has higher than normal MIC to this antimicrobial agent 
but is still considered susceptible by the NCCLS inter-
pretative criteria (23,24).
  In the present study, 76% of the isolates were nali-
dixic acid-resistant, and all appeared to be susceptible 
to ciprofloxacin in disc-diffusion testing. MIC of cipro-
floxacin for these NARST tested ranged from 0.25 to 1 
mg/L. It demonstrates that S. Typhi, less susceptible to 
ciprofloxacin, are prevalent in our area. Similar findings 
have been reported from studies conducted in central 
Nepal (8,18,19).
  The requirement for higher concentrations of cipro-
floxacin for the inhibition of S. Typhi could be due to 
the overuse of ciprofloxacin in the treatment of typhoid 
and in other unrelated infections. Over-the-counter 
availability of antibiotics and incomplete treatment due 
to many reasons in a developing country like ours may 
also be the factors contributing to the development of 
resistance. 
  Single-point mutation in quinolone resistance-de-
termining region of the topoisomerase gene gyrA in 
Salmonella usually leads to simultaneous resistance 
against nalidixic acid and decreased susceptibility to 
ciprofloxacin (4,24,28-30). Nalidixic acid resistance 
has been validated as a screening test for reduced sus-
ceptibility to ciprofloxacin. Identification of resistance 
to nalidixic acid by disc-diffusion provides a sensitive 
indicator of low-level resistance to ciprofloxacin. The 
NCCLS currently recommends the testing of extra-in-
testinal Salmonella isolates for reduced susceptibility to 
fluoroquinolones (31). However, there are strains of S. 
Typhi with decreased susceptibility to ciprofloxacin but 
susceptible to nalidixic acid. Detection of a number of 
such strains in the present study deserves a mention. A 
similar finding was observed in an Indian study and also 
in an European study (6,32). 
  All the isolates, including NARST strains, were sus-
ceptible to ceftriaxone, although ceftriaxone-resistant 
S. Typhi was reported elsewhere (33). This finding may 
be important for considering the use of this antibiotic 
for treating infection with MDR S. Typhi resistant to 
ciprofloxacin in this region. It is also of paramount im-
portance to limit its therapeutic use to only when the 
first-line and second-line drugs fail to evoke a satisfac-
tory response or when the isolate is resistant to nalidixic 
acid. High cost, need for parenteral administration, and 
poor penetration of cephalosporin into the infected cells, 
thus, leading to the requirement of a prolonged course 
are the major limiting factors, despite being the drug of 
choice for the treatment of quinolone-resistant typhoid 
fever.
  Over the recent years, azithromycin has also been 
used as the option for the treatment of MDR and qui-
nolone-resistant typhoid fever (4,34). However, its high 
cost and limited availability in endemic areas are again 
the major disadvantages.
  Activity of antimicrobials on S. Typhi appears to be 
changing over the past decade. From nalidixic acid to 
ciprofloxacin, development of resistance has steadily 
progressed. Although not a major problem at present, 
there are sporadic reports of ceftriaxone-resistant S. 
Typhi (33). Moreover, detection of integrons in isolates 
of S. Typhi from Asia has suggested that this organ-
ism has the potential for the acquisition of new resist-
ant  genes  (35,36).  Concerns  have  been  raised  about 
the emergence of effectively untreatable typhoid in the 
developing nations if the appropriate control measures 
are not taken on time (4,34). The prudent use of anti-
biotics and effective hospital infection-control practice 
may play a crucial role in preventing the emergence and 
spread of resistant organisms. At this point of time, it is 
also important to consider the necessity of development 
and evaluation of newer antimicrobials with different 
target site and mechanisms of action as the need for an 
alternative drug becomes evident.
  In conclusion, the findings of the present study 
indicate that MDR strains prevail in eastern Nepal. S. 
Typhi with reduced susceptibility to ciprofloxacin has 
emerged, thus narrowing the spectrum of availability 
of antibiotics for the treatment of this infection, often 
endemic sometimes taking epidemic proportions. 
Resistance of nalidixic acid as a screening test for de-
tecting reduced susceptibility to the quinolone group of 
drugs merits consideration. This simple disc-diffusion 
test can predict probable treatment failures and, thus, 
obviate the need for time-consuming dilution tests. De-
termination of MIC is still useful not only to detect the 
exact inhibitory concentration but also to confirm the 
less-susceptible strains which may indicate the develop-
ment of impending resistance among the local isolates. 
It is also important that microbiology laboratories have 
to decide on the optimal approach for timely detection 
of resistant strains depending upon their workflow and 
available resources. 
Drug-resistant S. Typhi in eastern Nepal 85This laboratory-based study highlights the patterns of S. 
Typhi in a hospital set up in eastern Nepal. As the major-
ity of typhoid fever patients are treated on a outpatient 
basis, a detailed information on the presenting features, 
time for defervescence, and response to therapy could 
not be obtained. Therefore, on the basis of observations 
made in this study, a further surveillance on typhoid fe-
ver and its clinical and epidemiological correlation with 
the resistant and susceptible strain is recommended.
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